# Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

> **NCT07019337** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 100 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07019337
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2028-07-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07019337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07019337, "Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07019337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*